WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555591
Description: UDM-001651 is a potent , selective and orally active Protease-Activated Receptor 4 (PAR4) Antagonist with in Vivo Antithrombotic Efficacy (IC50 = 2.4 nM). UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism.
MedKoo Cat#: 555591
Chemical Formula: C28H23N3O5S
Exact Mass: 513.1358
Molecular Weight: 513.568
Elemental Analysis: C, 65.48; H, 4.51; N, 8.18; O, 15.58; S, 6.24
Synonym: UDM-001651; UDM 001651; UDM001651; UDM-1651; UDM 1651; UDM1651;
IUPAC/Chemical Name: 6-(4-((3-(Benzyloxy)benzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-b][1,3,4]thiadiazole
InChi Key: LFOIDLOIBZFWDO-UHFFFAOYSA-N
InChi Code: InChI=1S/C28H23N3O5S/c1-32-21-12-24(35-17-19-9-6-10-20(11-19)34-16-18-7-4-3-5-8-18)22-14-26(36-25(22)13-21)23-15-31-27(29-23)37-28(30-31)33-2/h3-15H,16-17H2,1-2H3
SMILES Code: COC1=NN2C(S1)=NC(C3=CC4=C(OCC5=CC=CC(OCC6=CC=CC=C6)=C5)C=C(OC)C=C4O3)=C2
Atherothrombotic cardiovascular and cerebrovascular diseases are the leading cause of morbidity and mortality in developed countries and claim more lives each year than cancer in the United States.1 Atherothrombotic diseases, such as acute coronary syndrome and stroke, originate with a gradual buildup of plaque in the arterial wall. The eventual rupture of an atherosclerotic plaque exposes a prothrombotic milieu to the blood and activates platelets at the site of the injury, leading to the formation of a potentially occlusive thrombus and subsequent ischemia.
1: Miller MM, Banville J, Friends TJ, Gagnon M, Hangeland JJ, Lavallée JF, Martel
A, O'Grady H, Rémillard R, Ruediger E, Tremblay F, Posy SL, Allegretto NJ,
Guarino VR, Harden DG, Harper TW, Hartl K, Josephs J, Malmstrom S, Watson C, Yang
Y, Zhang G, Wong P, Yang J, Bouvier M, Seiffert DA, Wexler RR, Lawrence RM,
Priestley ES, Marinier A. Discovery of Potent Protease-Activated Receptor 4
Antagonists with in Vivo Antithrombotic Efficacy. J Med Chem. 2019 Aug 5. doi:
10.1021/acs.jmedchem.9b00186. [Epub ahead of print] PubMed PMID: 31246024.